Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| MRNA | Moderna, Inc. | -6.73% | 146.81 | 0.0% | $1534.10m | |
| OCGN | Ocugen, Inc. | -4.19% | 9.60 | 0.0% | $1069.86m | |
| NVAX | Novavax, Inc. | -14.27% | 205.99 | 92.9% | $909.19m | |
| AMGN | Amgen, Inc. | -0.60% | 225.69 | 1.3% | $548.32m | |
| VRTX | Vertex Pharmaceuticals, Inc. | 0.80% | 212.06 | 1.9% | $521.91m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -1.77% | 454.86 | 2.7% | $509.91m | |
| ILMN | Illumina, Inc. | -1.23% | 441.01 | 3.5% | $504.66m | |
| GILD | Gilead Sciences, Inc. | 0.88% | 63.01 | 1.0% | $479.35m | |
| ALXN | Alexion Pharmaceuticals, Inc. | -1.05% | 150.37 | 2.0% | $354.39m | |
| BNGO | Bionano Genomics, Inc. | -3.66% | 9.48 | 0.0% | $340.06m | |
| BIIB | Biogen, Inc. | -1.24% | 269.85 | 1.7% | $329.36m | |
| CRSP | CRISPR Therapeutics AG | -0.37% | 129.77 | 0.6% | $302.39m | |
| EXAS | EXACT Sciences Corp. | -2.72% | 136.39 | 18.4% | $253.67m | |
| SGEN | Seagen Inc. | 0.76% | 153.71 | 5.8% | $214.53m | |
| VXRT | Vaxart, Inc. | -5.43% | 7.14 | 0.0% | $189.51m |
Company Profile
Progenics Pharmaceuticals, Inc., of Tarrytown, N.Y., is a biopharmaceutical company focused on innovative therapeutics for patients suffering from cancer and related conditions. Progenics' pipeline candidates include PSMA ADC, a human monoclonal antibody-drug conjugate in phase 2 testing for treatment of prostate cancer, and preclinical stage novel multiplex phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer. Progenics has exclusively licensed development and commercialization rights for its first commercial product, RELISTOR®, to Salix Pharmaceuticals, Ltd. for markets worldwide other than Japan, where Ono Pharmaceutical Co., Ltd. holds an exclusive license for the subcutaneous formulation. RELISTOR (methylnaltrexone bromide) Subcutaneous Injection is a first-in-class treatment for opioid-induced constipation approved in more than 50 countries for patients with advanced illness.